Cephalon (CEPH) Rejects Valeant's (VRX) $73/Share Offer
Tweet
Share
E-mail
Get Alerts CEPH Hot Sheet
Join SI Premium – FREE
Cephalon, Inc. (NASDAQ: CEPH) formally rejected Valeant Pharmaceuticals' (NYSE: VRX) $73 per share unsolicited takeover proposal calling it "inadequate and not in the best interests of Cephalon's shareholders."
Cephalon said the offer significantly undervalues the company, values the company using a "worst-case scenario," is opportunistic and based off 52-week lows, and ascribes little to no value to the company's pipeline.
Cephalon said the offer significantly undervalues the company, values the company using a "worst-case scenario," is opportunistic and based off 52-week lows, and ascribes little to no value to the company's pipeline.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- Barclays sees solid first-half delivery for this European utility firm, while grid investment offers upside
- Kenon Holdings (KEN) halted, news pending
Create E-mail Alert Related Categories
Hot List, Hot M&A, Mergers and Acquisitions, Trading HaltsRelated Entities
Valeant Pharmaceuticals/Cephalon, Inc.Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
